|1.||Zhang, Donna D: 3 articles (11/2015 - 01/2011)|
|2.||Wu, Tongde: 2 articles (11/2015 - 01/2011)|
|3.||Wong, Pak K: 2 articles (11/2015 - 12/2014)|
|4.||Harder, Bryan G: 1 article (11/2015)|
|5.||Lang, Julie E: 1 article (11/2015)|
|6.||Ingelman-Sundberg, Magnus: 1 article (01/2015)|
|7.||Kitteringham, Neil R: 1 article (01/2015)|
|8.||Wong, Min Wei: 1 article (01/2015)|
|9.||Alghanem, Ahmad F: 1 article (01/2015)|
|10.||Lai, Zheng-Quan: 1 article (01/2015)|
|1.||Lung Neoplasms (Lung Cancer)
07/01/1979 - "XXXIV: Mechanism of action of bruceoside A and brusatol on nucleic acid metabolism of P-388 lymphocytic leukemia cells."
04/01/1982 - "A series of brusatol, bisbrusatol, and bruceantin esters were examined for their ability to inhibit protein synthesis in P-388 lymphocytic leukemia cells. "
03/01/1982 - "Antitumor agents XLVI: In vitro effects of esters of brusatol, bisbrusatol, and related compounds on nucleic acid and protein synthesis of P-388 lymphocytic leukemia cells."
07/01/1979 - "XXXV: Effects of brusatol, bruceoside A, and bruceantin on P-388 lymphocytic leukemia cell respiration."
07/01/1979 - "Brusatol, a quassinoid with potent antineoplastic activity against P-388 lymphocytic leukemia cell proliferation, significantly inhibited P-388 cell hexokinase, phosphofructokinase, malic dehydrogenase, and succinic dehydrogenase. "
12/01/2011 - "Among them, brusatol exhibited the most potent in vitro antipancreatic cancer action, with IC(50) values of 0.36 µm and 0.10 µm on PANC-1 and SW1990 cell lines, respectively. "
11/01/2015 - "Nrf2 inhibitors, such as brusatol, have the potential to be developed into novel adjuvant chemotherapeutic drug combinations in order to combat refractory tumor initiating CSCs. "
01/25/2011 - "In A549 xenografts, brusatol and cisplatin cotreatment induced apoptosis, reduced cell proliferation, and inhibited tumor growth more substantially when compared with cisplatin treatment alone. "
01/25/2011 - "Here, we report the identification of brusatol as a unique inhibitor of the Nrf2 pathway that sensitizes a broad spectrum of cancer cells and A549 xenografts to cisplatin and other chemotherapeutic drugs. "
09/01/1996 - "A novel lignan, guaiacylglycerol-beta-O-6'-(2-methoxy)cinnamyl alcohol either, three known simaroubolides, brusatol, dehydrobrusatol, yadanziolide C, and the known terpenoid, blumenol A, were obtained as active compounds from an ethyl acetate-soluble extract of Brucea javanica, using a bioassay based on the induction of cell differentiation with human promyelocytic leukemia (HL-60) cells. "
|5.||Hepatocellular Carcinoma (Hepatoma)
|5.||NF-E2-Related Factor 2
|8.||Tetrahydrofolate Dehydrogenase (Dihydrofolate Reductase)
|9.||Succinate Dehydrogenase (Fumarate Reductase)
|10.||DNA-Directed RNA Polymerases (RNA Polymerase)
|1.||Heterologous Transplantation (Xenotransplantation)